Memantine for AIDS dementia complex: open-label report of ACTG 301.

ABSTRACT:

Objective

To evaluate the long-term safety and efficacy of memantine use as treatment of HIV-associated cognitive impairment.

Background

The results of a 20-week, randomized, double-blind, placebo-controlled trial of memantine in HIV-infected participants with cognitive impairment (ACTG 301) were previously reported. We report the results of the up-to-60-week open-label phase following the double-blind phase.

Method

Participants received open-label memantine and were escalated to a 40 mg/day dose or their maximum tolerated dose in the double- blind phase. Adverse experiences were used to evaluate safety, and changes in the mean of eight neuropsychological test scores (NPZ-8) were used to evaluate efficacy.

Results

Ninety-nine participants entered the initial 12

SUBMITTER: Zhao Y 

PROVIDER: S-EPMC2981797 | biostudies-literature | 2010 Jan-Feb

REPOSITORIES: biostudies-literature